Do investors value the FDA orphan drug designation?

Do investors value the FDA orphan drug designation?

Abstract Background The Orphan Drug Act is an important piece of legislation that uses financial incentives to encourage the development of drugs that treat rare diseases. This analysis studies the effects of a portion of the Orphan Drug Act, the orphan drug designation. Specifically, it studies the...

Full description

Bibliographic Details
Main Author: Kathleen L. Miller
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Orphan designation
Event study
Investors
FDA
Online Access:http://link.springer.com/article/10.1186/s13023-017-0665-6

Internet

http://link.springer.com/article/10.1186/s13023-017-0665-6

Similar Items